新冠病毒检测与药物研发 |
|
|
|
|
抗新冠肺炎药物研究进展 |
许叶春,柳红,李剑峰,沈敬山,蒋华良() |
中国科学院上海药物研究所 上海 201203 |
|
Recent Progress in Drug Development against COVID-19 |
XU Ye-chun,LIU Hong,LI Jian-feng,SHEN Jing-shan,JIANG Hua-liang() |
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China |
引用本文:
许叶春,柳红,李剑峰,沈敬山,蒋华良. 抗新冠肺炎药物研究进展[J]. 中国生物工程杂志, 2021, 41(6): 111-118.
XU Ye-chun,LIU Hong,LI Jian-feng,SHEN Jing-shan,JIANG Hua-liang. Recent Progress in Drug Development against COVID-19. China Biotechnology, 2021, 41(6): 111-118.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.2105053
或
https://manu60.magtech.com.cn/biotech/CN/Y2021/V41/I6/111
|
[1] |
中华人民共和国国务院新闻办公室. 抗击新冠肺炎疫情的中国行动. 北京: 人民出版社, 2020.
|
|
The State Council Information Office of the People’s Republice of China. Fighting COVID-19 China in action. Beijing: People’s Publishing House, 2020.
|
[2] |
Saha R P, Sharma A R, Singh M K, et al. Repurposing drugs, ongoing vaccine, and new therapeutic development initiatives against COVID-19. Frontiers in Pharmacology, 2020, 11:1258.
doi: 10.3389/fphar.2020.01258
|
[3] |
Yu F, Xiang R, Deng X Q, et al. Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. Signal Transduction and Targeted Therapy, 2020, 5(1):212.
doi: 10.1038/s41392-020-00318-0
|
[4] |
Wang M L, Cao R Y, Zhang L K, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research, 2020, 30:269-271.
doi: 10.1038/s41422-020-0282-0
|
[5] |
Malin J J, Suárez I, Priesner V, et al. Remdesivir against COVID-19 and other viral diseases. Clinical Microbiology Reviews, 2020, 34(1):e00162-20.
|
[6] |
Wang Y M, Zhang D Y, Du G H, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 2020, 395(10236):1569-1578.
doi: 10.1016/S0140-6736(20)31022-9
|
[7] |
Spinner C D, Gottlieb R L, Criner G J, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA, 2020, 324(11):1048-1057.
doi: 10.1001/jama.2020.16349
|
[8] |
Beigel J H, Tomashek K M, Dodd L E, et al. Remdesivir for the treatment of COVID-19-final report. New England Journal of Medicine, 2020, 383(19):1813-1826.
doi: 10.1056/NEJMoa2007764
|
[9] |
Keyaerts E, Vijgen L, Maes P, et al. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochemical and Biophysical Research Communications, 2004, 323(1):264-268.
doi: 10.1016/j.bbrc.2004.08.085
|
[10] |
Chang R, Sun W Z. Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges. Drug Discovery Today, 2020, 25(10):1786-1792.
doi: 10.1016/j.drudis.2020.06.030
|
[11] |
Gautret P, Lagier J C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents, 2020, 56(1):105949.
doi: 10.1016/j.ijantimicag.2020.105949
|
[12] |
Huang M X, Li M, Xiao F, et al. Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19. National Science Review, 2020, 7(9):1428-1436.
doi: 10.1093/nsr/nwaa113
|
[13] |
Yu B, Li C Z, Chen P, et al. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Science China Life Sciences, 2020, 63(10):1515-1521.
doi: 10.1007/s11427-020-1732-2
|
[14] |
Yu B, Li C Z, Chen P, et al. Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs. Science China Life Sciences, 2021, 64(2):330-333.
doi: 10.1007/s11427-020-1782-1
|
[15] |
Hoffmann M, Mösbauer K, Hofmann-Winkler H, et al. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. Nature, 2020, 585(7826):588-590.
doi: 10.1038/s41586-020-2575-3
pmid: 32698190
|
[16] |
Maisonnasse P, Guedj J, Contreras V, et al. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. Nature, 2020, 585(7826):584-587.
doi: 10.1038/s41586-020-2558-4
pmid: 32698191
|
[17] |
Cavalcanti A B, Zampieri F G, Rosa R G, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate COVID-19. The New England Journal of Medicine, 2020, 383(21):2041-2052.
doi: 10.1056/NEJMoa2019014
|
[18] |
Jin Z M, Du X Y, Xu Y C, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature, 2020, 582(7811):289-293.
doi: 10.1038/s41586-020-2223-y
|
[19] |
Xiong R, Zhang L K, Li S L, et al. Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2. Protein & Cell, 2020, 11(10):723-739.
|
[20] |
Xu Y C, Jiang H L. Potential treatment of COVID-19 by inhibitors of human dihydroorotate dehydrogenase. Protein & Cell, 2020, 11(10):699-702.
|
[21] |
Hu K, Wang M M, Zhao Y, et al. A small-scale medication of leflunomide as a treatment of COVID-19 in an open-label blank-controlled clinical trial. Virologica Sinica, 2020, 35(6):725-733.
doi: 10.1007/s12250-020-00258-7
|
[22] |
Dai W H, Zhang B, Jiang X M, et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science, 2020, 368(6497):1331-1335.
doi: 10.1126/science.abb4489
|
[23] |
Yin W C, Mao C Y, Luan X D, et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science, 2020, 368(6498):1499-1504.
|
[24] |
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 2020, 181(2): 271-280.e8.
doi: S0092-8674(20)30229-4
pmid: 32142651
|
[25] |
Ju B, Zhang Q, Ge J W, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature, 2020, 584(7819):115-119.
doi: 10.1038/s41586-020-2380-z
|
[26] |
Shi R, Shan C, Duan X M, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature, 2020, 584(7819):120-124.
doi: 10.1038/s41586-020-2381-y
|
[27] |
Cao Y L, Su B, Guo X H, et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Cell, 2020, 182(1): 73-84.e16.
doi: 10.1016/j.cell.2020.05.025
|
[28] |
Tang Y L, Wang Z H, Huo C Y, et al. Antiviral effects of Shuanghuanglian injection powder against influenza A virus H5N1 in vitro and in vivo. Microbial Pathogenesis, 2018, 121:318-324.
doi: 10.1016/j.micpath.2018.06.004
|
[29] |
Su H X, Yao S, Zhao W F, et al. Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. Acta Pharmacologica Sinica, 2020, 41(9):1167-1177.
doi: 10.1038/s41401-020-0483-6
|
[30] |
Ni L, Zhou L, Zhou M, et al. Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19. Frontiers of Medicine, 2020, 14(2):210-214.
doi: 10.1007/s11684-020-0757-x
|
[31] |
Ni L, Wen Z, Hu X W, et al. Effects of Shuanghuanglian oral liquids on patients with COVID-19: a randomized, open-label, parallel-controlled, multicenter clinical trial. Frontiers of Medicine, 2021, https://doi.org/10.1007/s11684-021-0853-6.
|
[32] |
Ding Y W, Zeng L J, Li R F, et al. The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function. BMC Complementary and Alternative Medicine, 2017, 17(1):130.
doi: 10.1186/s12906-017-1585-7
|
[33] |
Li R F, Hou Y L, Huang J C, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacological Research, 2020, 156:104761.
doi: 10.1016/j.phrs.2020.104761
|
[34] |
Hu K, Guan W J, Bi Y, et al. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial. Phytomedicine, 2021, 85:153242.
doi: 10.1016/j.phymed.2020.153242
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|